Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Razadyne vs Aricept fMRI in Mild Alzheimer's
NCT00369603Phase 4Terminated
- Sponsor
- Duke University
- Start
- Oct 2006
- Primary completion
- Oct 2007
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of galantamine in Alzheimer's disease (AD) (2 arms), sponsored by Duke University. Primary endpoint: Brain activity patterns via fMRI at 12 weeks. Started Oct 2006; status: terminated.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00369603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369603.